{
  "id": "map_1860",
  "title": "OFTALMOPAT√çA\\NDISTIROIDEA (ODT)",
  "specialty": "Endocrinolog√≠a",
  "tag": "üìã Gu√≠a Cl√≠nica",
  "node_count": 163,
  "root": {
    "text": "OFTALMOPAT√çA\\NDISTIROIDEA (ODT)",
    "children": [
      {
        "text": "DEFINICI√ìN",
        "children": [
          {
            "text": "Enfermedad ocular autoinmune + inflamaci√≥n tejidos orbitarios",
            "children": []
          }
        ]
      },
      {
        "text": "EPIDEMIOLOG√çA",
        "children": [
          {
            "text": "50% pacientes con Graves ‚Üí diagn√≥stico cl√≠nico",
            "children": []
          },
          {
            "text": "Relaci√≥n con\\Nestado tiroideo:",
            "children": [
              {
                "text": "90% ‚Üí hipertiroidismo",
                "children": []
              },
              {
                "text": "10% ‚Üí otras etapas (eutiroidismo/hipotiroidismo postratamiento)",
                "children": []
              }
            ]
          },
          {
            "text": "Gravedad:",
            "children": [
              {
                "text": "20-30% ‚Üí cl√≠nicamente relevante",
                "children": []
              },
              {
                "text": "5% ‚Üí grave (neuropat√≠a √≥ptica distiroidea)",
                "children": []
              }
            ]
          }
        ]
      },
      {
        "text": "FISIOPATOLOG√çA",
        "children": [
          {
            "text": "Inicio ‚Üí Linfocitos vs ant√≠genos comunes tiroides/√≥rbitas",
            "children": []
          },
          {
            "text": "Proceso: ‚Üë Vol. m√∫sculos extraoculares + tejido conjuntivo/adiposo retroorbitario\\N‚Üí ‚Ä¢ Inflamaci√≥n ‚Ä¢ ‚Üë GAG (glucosaminoglicanos) hidrof√≠licos + √°c. hialur√≥nico",
            "children": []
          },
          {
            "text": "Mecanismo: C√©lulas T ‚Üí ‚Üëcitoquinas (TNF-Œ± + interfer√≥n-Œ≥) ‚Üí Fibroblastos ‚Üí ‚ÜëGAG\\N‚Üí ‚ÜëPresi√≥n osm√≥tica ‚Üí ‚Üël√≠quido ‚Üí ‚ÜëPresi√≥n intraorbitaria ‚Üí",
            "children": [
              {
                "text": "‚ÜìDrenaje venoso",
                "children": []
              },
              {
                "text": "‚ÜìMovilidad m√∫sculos extraoculares",
                "children": []
              },
              {
                "text": "Desplazamiento anterior √≥rbitas",
                "children": []
              }
            ]
          }
        ]
      },
      {
        "text": "CAUSA\\NPROBABLE",
        "children": [
          {
            "text": "Activaci√≥n inmune √ó TRab en adipocitos/fibroblastos orbitarios",
            "children": []
          },
          {
            "text": "Otros autoant√≠genos posibles: anti-IGF-1 + tiroglobulina",
            "children": []
          }
        ]
      },
      {
        "text": "DIAGN√ìSTICO\\NDIFERENCIAL",
        "children": [
          {
            "text": "Esp. forma unilateral\\N‚Üí considerar:",
            "children": [
              {
                "text": "Pseudotumor orbitario",
                "children": []
              },
              {
                "text": "Miositis orbitaria",
                "children": []
              },
              {
                "text": "F√≠stula seno cavernoso",
                "children": []
              },
              {
                "text": "Celulitis orbitaria",
                "children": []
              },
              {
                "text": "Tumores orbitarios",
                "children": []
              },
              {
                "text": "Miop√≠a grave",
                "children": []
              }
            ]
          }
        ]
      },
      {
        "text": "EVALUACI√ìN\\NCL√çNICA",
        "children": [
          {
            "text": "2 par√°metros complementarios: \\N‚Üí Evaluar simult√°neamente ambos par√°metros",
            "children": [
              {
                "text": "Actividad (inflamaci√≥n)\\N‚Üí Escala CAS",
                "children": [
                  {
                    "text": "‚Ä¢ Score ‚â•3 ‚Üí activa ",
                    "children": []
                  },
                  {
                    "text": "‚Ä¢ Score <3 ‚Üí inactiva",
                    "children": []
                  }
                ]
              },
              {
                "text": "Gravedad ",
                "children": []
              }
            ]
          }
        ]
      },
      {
        "text": "EVALUACI√ìN ODT",
        "children": [
          {
            "text": "Escala de Actividad Cl√≠nica (CAS)\\NPuntaje: 1 punto c/u",
            "children": [
              {
                "text": "‚Ä¢ Dolor retroocular espont√°neo",
                "children": []
              },
              {
                "text": "‚Ä¢ Dolor en movimientos oculares",
                "children": []
              },
              {
                "text": "‚Ä¢ Enrojecimiento de p√°rpados",
                "children": []
              },
              {
                "text": "‚Ä¢ Enrojecimiento conjuntival",
                "children": []
              },
              {
                "text": "‚Ä¢ Edema palpebral",
                "children": []
              },
              {
                "text": "‚Ä¢ Edema de car√∫ncula",
                "children": []
              },
              {
                "text": "‚Ä¢ Edema conjuntival (quemosis)",
                "children": []
              }
            ]
          },
          {
            "text": "Score de Gravedad\\Nde ODT",
            "children": [
              {
                "text": "1. Retracci√≥n\\Npalpebral:",
                "children": [
                  {
                    "text": "‚Ä¢ Leve: <2 mm",
                    "children": []
                  },
                  {
                    "text": "‚Ä¢ Moderada-grave: ‚â•2 mm",
                    "children": []
                  }
                ]
              },
              {
                "text": "2. Exoftalmo:",
                "children": [
                  {
                    "text": "‚Ä¢ Leve: <3 mm sobre m√°x. normal (raza/g√©nero)",
                    "children": []
                  },
                  {
                    "text": "‚Ä¢ Moderada-grave: ‚â•3 mm sobre m√°x. normal",
                    "children": []
                  }
                ]
              },
              {
                "text": "3. Tejidos\\Nblandos:",
                "children": [
                  {
                    "text": "‚Ä¢ Leve",
                    "children": []
                  },
                  {
                    "text": "‚Ä¢ Moderado-grave",
                    "children": []
                  }
                ]
              },
              {
                "text": "4. M√∫sculos extraoculares:\\N(Diplopia)",
                "children": [
                  {
                    "text": "‚Ä¢ Leve: Ninguno/intermitente",
                    "children": [
                      {
                        "text": "‚Ä¢ Intermitente: Fatiga/despertar",
                        "children": []
                      }
                    ]
                  },
                  {
                    "text": "‚Ä¢ Moderado-grave: Inconstante/constante",
                    "children": [
                      {
                        "text": "‚Ä¢ Inconstante: Extremos de mirada",
                        "children": []
                      },
                      {
                        "text": "‚Ä¢ Constante: Mirada al frente/abajo",
                        "children": []
                      }
                    ]
                  }
                ]
              },
              {
                "text": "5. Compromiso\\Ncorneal:",
                "children": [
                  {
                    "text": "‚Ä¢ Leve: Ausente/leve",
                    "children": []
                  },
                  {
                    "text": "‚Ä¢ Moderado",
                    "children": []
                  }
                ]
              }
            ]
          }
        ]
      },
      {
        "text": "DERIVACI√ìN\\NOFTALMOL√ìGICA",
        "children": [
          {
            "text": "ODT moderada-grave ‚Üí evaluaci√≥n/seguimiento",
            "children": []
          },
          {
            "text": "Urgente si: ",
            "children": [
              {
                "text": "‚Ä¢ ‚ÜìVisual aguda ‚Ä¢ Alteraci√≥n visi√≥n colores ‚Ä¢ Subluxaci√≥n globo ocular\\N‚Ä¢ Opacidad corneal ‚Ä¢ Exposici√≥n corneal",
                "children": []
              }
            ]
          }
        ]
      },
      {
        "text": "FACTORES\\NRIESGO",
        "children": [
          {
            "text": "Gen√©tico: ‚Ä¢ Antecedente\\Npersonal/familiar:",
            "children": [
              {
                "text": "Graves",
                "children": []
              },
              {
                "text": "Tiroiditis Hashimoto",
                "children": []
              },
              {
                "text": "Otras enf. autoinmunes",
                "children": []
              }
            ]
          },
          {
            "text": "Sexo: ‚Ä¢ + frecuente mujeres ‚Ä¢ Hombres ‚Üí evoluci√≥n + grave",
            "children": []
          },
          {
            "text": "Tabaco (4,5): ‚Ä¢ Riesgo 7.7√ó > en fumadores\\N‚Ä¢ Mecanismo:",
            "children": [
              {
                "text": "‚Üëvolumen tejido conectivo orbital",
                "children": []
              },
              {
                "text": "‚ÜëGAG + adipog√©nesis ‚Üí\\Nexposici√≥n-dependiente",
                "children": [
                  {
                    "text": "‚Ä¢ Recomendaci√≥n: cese inmediato en\\Ntodo paciente Graves (esp. con ODT)",
                    "children": []
                  }
                ]
              }
            ]
          },
          {
            "text": "Disfunci√≥n\\Ntiroidea:",
            "children": [
              {
                "text": "‚Ä¢ Hipertiroidismo persistente ‚Üí + riesgo ODT grave",
                "children": []
              },
              {
                "text": " ‚Ä¢ Hipotiroidismo ‚Üí delet√©reo √ó ‚ÜëTSH ",
                "children": []
              }
            ]
          },
          {
            "text": "Tratamiento\\Nhipertiroidismo:",
            "children": [
              {
                "text": "‚Ä¢ I131 ‚Üí + riesgo vs tionamidas/cirug√≠a",
                "children": []
              },
              {
                "text": "‚Ä¢ Post-I131: 15% casos ‚Üí ODT nueva/progresi√≥n (2-6 meses)",
                "children": []
              },
              {
                "text": "‚Ä¢ Prevenci√≥n: glucocorticoides + I131",
                "children": []
              }
            ]
          },
          {
            "text": "TRab: ",
            "children": [
              {
                "text": "‚Ä¢ T√≠tulos elevados ‚Üí + frecuencia/gravedad ODT",
                "children": []
              }
            ]
          },
          {
            "text": "Otros:",
            "children": [
              {
                "text": "‚Ä¢ Edad >60 a√±os ‚Ä¢ Estr√©s",
                "children": []
              }
            ]
          }
        ]
      },
      {
        "text": "RECOMENDACIONES\\NDIAGN√ìSTICAS",
        "children": [
          {
            "text": "Medici√≥n\\NTRab:",
            "children": [
              {
                "text": "‚Ä¢ Justificada en todo paciente ODT\\N‚Ä¢ Especial utilidad:",
                "children": [
                  {
                    "text": "Duda diagn√≥stica",
                    "children": []
                  },
                  {
                    "text": "ODT + eutiroidismo",
                    "children": []
                  },
                  {
                    "text": "Predictor gravedad",
                    "children": []
                  }
                ]
              }
            ]
          },
          {
            "text": "TAC sin contraste/RM √≥rbita:\\N‚Ä¢ Indicaciones:",
            "children": [
              {
                "text": "Sospecha neuropat√≠a √≥ptica",
                "children": []
              },
              {
                "text": "Score de gravedad de ODT (+)\\NElementos gravedad",
                "children": []
              },
              {
                "text": "Dx diferencial otras patolog√≠as",
                "children": [
                  {
                    "text": "Exoftalmo unilateral/eutiroideos ",
                    "children": []
                  }
                ]
              }
            ]
          },
          {
            "text": "Profilaxis corticoides en ODT + I131:\\N‚Ä¢ Indicaciones:",
            "children": [
              {
                "text": "CAS ‚â•3 puntos/score gravedad moderada",
                "children": []
              },
              {
                "text": "Factores\\Nriesgo:",
                "children": [
                  {
                    "text": "‚Ä¢ TRab >7.5-10 U/L (normal <1. 5) ‚Ä¢ Tabaquismo ‚Ä¢ Orbitopat√≠a preexistente\\N‚Ä¢ Contraindicaci√≥n: ODT grave",
                    "children": []
                  }
                ]
              }
            ]
          }
        ]
      },
      {
        "text": "MANEJO ODT",
        "children": [
          {
            "text": "CORTICOIDES + I131",
            "children": [
              {
                "text": "Prednisona 0.3-0.5 mg/kg/d:",
                "children": [
                  {
                    "text": "Inicio: d√≠a 1 a 3 post-I131",
                    "children": []
                  },
                  {
                    "text": "‚Üìprogresiva hasta suspender al 3er mes",
                    "children": []
                  }
                ]
              },
              {
                "text": "Levotiroxina si post-I131\\NSi T4 total <7 Œºg/dL",
                "children": [
                  {
                    "text": "Inicio: 50 Œºg/d a 3 sem",
                    "children": []
                  },
                  {
                    "text": "Independiente de TSH",
                    "children": []
                  },
                  {
                    "text": "Hipotiroidismo puede agravar la evoluci√≥n de la ODT",
                    "children": []
                  }
                ]
              }
            ]
          },
          {
            "text": "MEDIDAS\\NGENERALES",
            "children": [
              {
                "text": "‚Ä¢ Suspender tabaco",
                "children": []
              },
              {
                "text": " ‚Ä¢ Lentes oscuros ‚Üí fotofobia",
                "children": []
              },
              {
                "text": "‚Ä¢ L√°grimas artificiales/gel ‚Üí noches/mala oclusi√≥n",
                "children": []
              },
              {
                "text": "‚Ä¢ Parches oculares ‚Üí lagoftalmo",
                "children": []
              },
              {
                "text": "‚Ä¢ Prismas ‚Üí diplop√≠a",
                "children": []
              }
            ]
          },
          {
            "text": "ODT LEVE",
            "children": [
              {
                "text": "‚Ä¢ Solo observaci√≥n + medidas generales",
                "children": []
              },
              {
                "text": "‚Ä¢ Selenio: 100 Œºg/12h √ó 6 meses",
                "children": [
                  {
                    "text": "Beneficios > placebo",
                    "children": []
                  },
                  {
                    "text": "No est√°ndar cl√≠nico actual ",
                    "children": []
                  }
                ]
              },
              {
                "text": "‚Ä¢ Si I131 ‚Üí evaluar profilaxis corticoides",
                "children": []
              }
            ]
          },
          {
            "text": "ODT Moderada-Grave + Activa\\N(CAS ‚â•3)",
            "children": [
              {
                "text": "A. Corticoides:",
                "children": [
                  {
                    "text": "‚Ä¢ VO: Prednisona 60 mg/d",
                    "children": []
                  },
                  {
                    "text": "‚Ä¢ IV: Metilprednisolona (mejores resultados)",
                    "children": []
                  }
                ]
              },
              {
                "text": "B. Esquemas IV",
                "children": [
                  {
                    "text": "‚Ä¢ Ambulatorio:",
                    "children": [
                      {
                        "text": "‚Ä¢ 500 mg/sem √ó 6 sem ‚Üí 250 mg/sem √ó 6 sem",
                        "children": []
                      }
                    ]
                  },
                  {
                    "text": "‚Ä¢ Hospitalario:",
                    "children": [
                      {
                        "text": "‚Ä¢ 1 g/60 min √ó 3 d√≠as consecutivos",
                        "children": []
                      }
                    ]
                  }
                ]
              },
              {
                "text": "C. Consideraciones\\NMetilprednisolona:",
                "children": [
                  {
                    "text": "‚Ä¢ Dosis acumulada m√°x: 8 g",
                    "children": []
                  },
                  {
                    "text": "‚Ä¢ Evaluar pre-tratamiento:",
                    "children": [
                      {
                        "text": "‚Ä¢ Funci√≥n hep√°tica, PA, √∫lcera p√©ptica, diabetes, glaucoma",
                        "children": []
                      }
                    ]
                  },
                  {
                    "text": "‚Ä¢ Monitorizaci√≥n\\Nhospitalaria:",
                    "children": [
                      {
                        "text": "‚Ä¢ Electrolitos/glucemia diaria",
                        "children": []
                      },
                      {
                        "text": "‚Ä¢ Manifestaciones psiqui√°tricas",
                        "children": []
                      }
                    ]
                  }
                ]
              }
            ]
          },
          {
            "text": "ODT Moderada-Grave + Inactiva\\N(CAS <3)",
            "children": [
              {
                "text": "‚Ä¢ Inactividad >6 meses",
                "children": []
              },
              {
                "text": "‚Ä¢ Tto quir√∫rgico\\Nreconstructivo:",
                "children": [
                  {
                    "text": "‚Ä¢ Descompresi√≥n orbital",
                    "children": []
                  },
                  {
                    "text": "‚Ä¢ Correcci√≥n retracci√≥n palpebral",
                    "children": []
                  },
                  {
                    "text": "‚Ä¢ Blefaroplastia",
                    "children": []
                  },
                  {
                    "text": "‚Ä¢ Correcci√≥n estrabismo",
                    "children": []
                  }
                ]
              }
            ]
          },
          {
            "text": "Neuropat√≠a\\N√ìptica",
            "children": [
              {
                "text": "Corticoides\\NSist√©micos:",
                "children": [
                  {
                    "text": "‚Ä¢ Metilprednisolona: 1 g IV/30-60 min √ó 3 d√≠as",
                    "children": []
                  },
                  {
                    "text": "‚Ä¢ Mejor√≠a\\N(2 sem):",
                    "children": [
                      {
                        "text": "‚Ä¢ Prednisona VO:",
                        "children": [
                          {
                            "text": "‚Ä¢ 40 mg/d √ó 2 sem ‚Üí",
                            "children": []
                          },
                          {
                            "text": "‚Ä¢ 30 mg/d √ó 4 sem ‚Üí",
                            "children": []
                          },
                          {
                            "text": "‚Ä¢ 20 mg/d √ó 4 sem ‚Üí ‚Üì progresiva hasta suspender",
                            "children": []
                          }
                        ]
                      },
                      {
                        "text": "‚Ä¢ Sin respuesta: Cirug√≠a descompresiva",
                        "children": []
                      }
                    ]
                  }
                ]
              },
              {
                "text": "Radioterapia",
                "children": [
                  {
                    "text": "‚Ä¢ Indicaciones:",
                    "children": [
                      {
                        "text": "‚Ä¢ √ötil en combinaci√≥n con corticoides",
                        "children": []
                      },
                      {
                        "text": "‚Ä¢ Especialmente en compromiso m√∫sculos extraoculares",
                        "children": []
                      }
                    ]
                  },
                  {
                    "text": "‚Ä¢ Contraindicaciones:",
                    "children": [
                      {
                        "text": "‚Ä¢ Retinopat√≠a diab√©tica",
                        "children": []
                      },
                      {
                        "text": "‚Ä¢ Retinopat√≠a hipertensiva grave",
                        "children": []
                      }
                    ]
                  }
                ]
              }
            ]
          }
        ]
      }
    ]
  },
  "related_maps": [
    {
      "id": "map_1633",
      "title": "ACV: ESCALAS DE UTILIDAD CL√çNICA"
    },
    {
      "id": "map_1673",
      "title": "DAPA-CKD (2020)\\NDapagliflozin And Prevention\\Nof Adverse outcomes in CKD\\N\\N‚≠ê iSGLT2 protege ri√±√≥n\\NINCLUSO SIN DIABETES\\N(Extiende beneficio a ERC no-DM)"
    },
    {
      "id": "map_1674",
      "title": "CREDENCE (2019)\\NCanagliflozin and Renal Events in Diabetes\\N\\nCanagliflozina reduce progresion ERC\\ny eventos CV en DM2 con nefropatia\\nNNTH 22 para outcome renal"
    },
    {
      "id": "map_1677",
      "title": "DAPA-HF (2019)\\NDapagliflozin in Heart Failure\\N\\nDapagliflozina reduce muerte CV y hospitalizacion IC\\nen IC-FEr CON y SIN diabetes\\NNNTH 21"
    },
    {
      "id": "map_1689",
      "title": "SPRINTT (2021)\\NSarcopenia and Physical\\NFragility in Older People:\\NMulti-component Treatment\\N\\n‚≠ê Ejercicio + nutrici√≥n reduce\\ndiscapacidad en fragilidad f√≠sica\\ncon sarcopenia"
    }
  ],
  "source_file": "Arteaga | OFTALMOPATIÃÅA DISTIROIDEA (ODT)-2024.smmx",
  "created": "2026-02-07T15:43:01.596349"
}